Actero Middle East is pleased to announce the launch of its first product to the Iranian market. This launch is a milestone for our young company, but it is only the first step towards building our oncology portfolio. Capecitabine ACTe 500 mg tablets are equivalent to Xeloda tablets, a chemotherapy medication used to treat breast cancer, gastric cancer and colorectal cancer. “The approval and launch of Capecitabine ACTe is good news for oncologists and patients that will have access to a wider range of quality products to choose from. We aim to make our products available in the market and hope to create more competition based solely on quality and let doctors make their choice.” Dr. Tiam Esfahani, Sales and Marketing Director Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.